The Real-World Clinical Benefits of Following Therapy after Trastuzumab Emtansine (T-DM1) for HER2-positive Metastatic Breast Cancer: A Multicentral Cohort Study(WJOG12519B)

The Real-World Clinical Benefits of Following Therapy after Trastuzumab Emtansine (T-DM1) for HER2-positive Metastatic Breast Cancer: A Multicentral Cohort Study(WJOG12519B) - Therapy after Trastuzumab Emtansine (T-DM1) for HER2-positive metastatic breast cancer(WJOG12519B)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037747

Enrollment

300

Registered

2019-08-26

Start date

2019-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It has been diagnosed as HER2-positive breast cancer by the pathological diagnosis. 2. It has been diagnosed with metastatic breast cancer (Stage IV breast cancer or recurrent breast cancer). 3. Between January 1st, 2014 and December 31st, 2018, at least one line of following treatment has begun after the first trastuzumeb emtansine (T-DM1) treatment for Stage IV breast cancer or recurrent breast cancer.

Exclusion criteria

Exclusion criteria: 1. The case where the following treatment after the first trastuzumeb emtansine (T-DM1) is registered in the clinical trial of derug development 2. Patients judged to be inappropriate as targets by the judgment of other doctors

Design outcomes

Primary

Measure	Time frame
Response rate of the next treatment after trastuzumab emtansine (T-DM1)	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results